pro rx tirzepatide Pros Weight Loss Program Compounder warned by FDA after

A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result

Key end points included: hospitalisation, heart failure (ICD-10-CM-I50), myocardial infarction (ICD-10-CM-I21), stroke and transient ischaemic attack (ICD-10-CM-I63, G45), development of diabetic microvascular complications (ICD-10-CM-E10.210.4) and all-cause mortality analysed 3 months to 5 years post drug initiation

The risk of hypoglycemia increases during periods of reduced food intake

Presented for research literature review only al-Ghais SM et al

Thus, there is a growing need for high-calorie, high protein and fiber content food products in a small amount

Research focuses on its impact on metabolism and cellular energy balance